Italian healthcare authorities have identified mosunetuzumab as a more cost-effective treatment option compared to tisagenlecleucel for adult patients battling relapsed or refractory follicular lymphoma (R/R FL) in their third or subsequent lines of therapy. This conclusion stems from a comprehensive economic evaluation conducted from the perspective of the Italian National Health Service (NHS).
Economic Impact of Treatment Choices
The analysis utilized a partitioned survival model over a lifetime horizon, meticulously tracking patient outcomes based on progression-free and overall survival rates. By integrating data from the GO29781 trial and adjusting for population differences through a matching-adjusted indirect treatment comparison (MAIC), researchers ensured a robust comparison between the two therapies. Direct medical costs, including drug expenses, administration, monitoring, and management of adverse events, were factored into the economic assessment.
Superior Clinical Outcomes with Cost Savings
Findings revealed that mosunetuzumab not only extended life expectancy by an additional 0.98 years and improved quality-adjusted life years (QALYs) by 0.70 but also reduced overall treatment costs. The sensitivity analysis reinforced these results, showing a 94% probability that mosunetuzumab remains cost-effective under the Italian willingness-to-pay threshold of €40,000 per QALY. Even when assuming equal overall survival rates, mosunetuzumab maintained its cost advantage due to lower incremental costs.
• Mosunetuzumab offers significant survival benefits over tisagenlecleucel.
• The treatment reduces financial burden on the Italian NHS.
• Cost-effectiveness remains robust across various sensitivity analyses.
• Lower incremental costs ensure sustainability even with clinical uncertainties.
This evaluation underscores the potential of mosunetuzumab to become the preferred treatment for R/R 3L+ FL patients within Italy, balancing both clinical efficacy and economic sustainability. By demonstrating enhanced patient outcomes alongside reduced costs, mosunetuzumab presents a compelling case for its integration into standard care protocols.
Healthcare policymakers and practitioners can leverage these insights to make informed decisions that optimize patient care while maintaining fiscal responsibility. The study emphasizes the importance of ongoing research and data collection to further validate these findings and address any long-term economic and clinical uncertainties associated with mosunetuzumab.
As the Italian NHS continues to navigate the complexities of cancer treatment funding, treatments like mosunetuzumab that offer both medical and economic advantages will likely play a crucial role in shaping future therapeutic strategies and resource allocation.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
